Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

10 May 2016 - 16 May 2016
11 May 2016 - 13 May 2016

Differential Production of Amyloid Proteins Marks Hereditary Alzheimer's Disease

By BiotechDaily International staff writers
Posted on 24 Jun 2013
Print article
Alzheimer's disease (AD) researchers employing SILK (stable isotope linked kinetics) technology have shown that individuals with a hereditary form of AD overproduce type 42 amyloid beta protein, which readily accumulates in the amyloid plaques that characterize the disease.

Most cases of Alzheimer's disease are not hereditary. However, there is a small subset of cases that have an earlier age of onset and a strong genetic element. In patients suffering from this form of Alzheimer's disease (autosomal dominant hereditary), mutations in the presenilin proteins (PSEN1 and PSEN2) or the amyloid precursor protein (APP) can be found. The majority of these cases carry mutant presenilin genes. An important factor in the disease process in AD is the accumulation of amyloid beta (Abeta) protein. To form Abeta, APP must be cut by two enzymes, beta secretases and gamma secretase. Presenilin is the sub-component of gamma secretase that is responsible for the cutting of APP.

Until the development of SILK, there was no method to directly measure the production or clearance of Abeta. The SILK technique, which was first described in 2006, requires 36 hours to perform, but is the only published method that allows measurement of amyloid plaque formation and clearance in the living brain.

Investigators at Washington University School of Medicine (St. Louis, MO, USA) recently used SILK technology to evaluate 11 subjects with Alzheimer’s mutations and compare the findings to those obtained from 12 related family members who did not have Alzheimer’s mutations.

Results revealed that the AD patients synthesized about 20% more Abeta42 than did family members who lacked the Alzheimer’s mutation. The fractional turnover rate of soluble Abeta42 relative to another form of amyloid protein Abeta40 was 65% faster in mutation carriers and correlated with amyloid deposition, consistent with increased deposition of Abeta42 into plaques, leading to reduced recovery of Abeta42 in cerebrospinal fluid (CSF).

“These results indicate how much we should target amyloid beta 42 with Alzheimer’s drugs,” said senior author Dr. Randall Bateman, professor of neurology at Washington University School of Medicine. “We are hopeful that this and other research will lead to preventive therapies to delay or even possibly prevent Alzheimer’s disease.”

The study was published in the June 12, 2013, issue of the journal Science Translational Medicine.

Related Links:
Washington University School of Medicine




Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.